199 related articles for article (PubMed ID: 36128328)
1. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
Ueno D; Vasquez JC; Sule A; Liang J; van Doorn J; Sundaram R; Friedman S; Caliliw R; Ohtake S; Bao X; Li J; Ye H; Boyd K; Huang RR; Dodson J; Boutros P; Bindra RS; Shuch B
Oncotarget; 2022; 13():1054-1067. PubMed ID: 36128328
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
[TBL] [Abstract][Full Text] [Related]
3. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
Sulkowski PL; Sundaram RK; Oeck S; Corso CD; Liu Y; Noorbakhsh S; Niger M; Boeke M; Ueno D; Kalathil AN; Bao X; Li J; Shuch B; Bindra RS; Glazer PM
Nat Genet; 2018 Aug; 50(8):1086-1092. PubMed ID: 30013182
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
[TBL] [Abstract][Full Text] [Related]
5. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
6. Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).
Ricketts CJ; Killian JK; Vocke CD; Wang Y; Merino MJ; Meltzer PS; Linehan WM
PLoS One; 2022; 17(12):e0278108. PubMed ID: 36455002
[TBL] [Abstract][Full Text] [Related]
7. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
8. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.
Lehtonen HJ; Mäkinen MJ; Kiuru M; Laiho P; Herva R; van Minderhout I; Hogendoorn PC; Cornelisse C; Devilee P; Launonen V; Aaltonen LA
Int J Cancer; 2007 Sep; 121(6):1386-9. PubMed ID: 17520677
[TBL] [Abstract][Full Text] [Related]
9. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
Schaefer IM; Hornick JL; Bovée JVMG
Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
11. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
Pollard PJ; Brière JJ; Alam NA; Barwell J; Barclay E; Wortham NC; Hunt T; Mitchell M; Olpin S; Moat SJ; Hargreaves IP; Heales SJ; Chung YL; Griffiths JR; Dalgleish A; McGrath JA; Gleeson MJ; Hodgson SV; Poulsom R; Rustin P; Tomlinson IP
Hum Mol Genet; 2005 Aug; 14(15):2231-9. PubMed ID: 15987702
[TBL] [Abstract][Full Text] [Related]
13. Oncometabolites suppress DNA repair by disrupting local chromatin signalling.
Sulkowski PL; Oeck S; Dow J; Economos NG; Mirfakhraie L; Liu Y; Noronha K; Bao X; Li J; Shuch BM; King MC; Bindra RS; Glazer PM
Nature; 2020 Jun; 582(7813):586-591. PubMed ID: 32494005
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.
Yoo A; Tang C; Zucker M; Fitzgerald K; DiNatale RG; Rappold PM; Weiss K; Freeman B; Lee CH; Schultz N; Motzer R; Russo P; Coleman J; Reuter VE; Chen YB; Carlo MI; Gill AJ; Kotecha RR; Ari Hakimi A; Reznik E
Eur Urol Focus; 2022 Sep; 8(5):1278-1288. PubMed ID: 35288096
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Kotecha RR; Doshi SD; Knezevic A; Chaim J; Chen Y; Jacobi R; Zucker M; Reznik E; McHugh D; Shah NJ; Feld E; Aggen DH; Rafelson W; Xiao H; Carlo MI; Feldman DR; Lee CH; Motzer RJ; Voss MH
Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37945488
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
17. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
18. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
Lai Y; Li Z; Lu Z; Zheng H; Chen C; Liu C; Yang Y; Tang F; He Z
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36263616
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Yuan AL; Meode M; Tan M; Maxwell L; Bering EA; Pedersen H; Willms J; Liao J; Black S; Cairncross JG; Blough MD
J Neurooncol; 2020 Jul; 148(3):463-472. PubMed ID: 32562246
[TBL] [Abstract][Full Text] [Related]
20. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase.
Frezza C; Zheng L; Folger O; Rajagopalan KN; MacKenzie ED; Jerby L; Micaroni M; Chaneton B; Adam J; Hedley A; Kalna G; Tomlinson IP; Pollard PJ; Watson DG; Deberardinis RJ; Shlomi T; Ruppin E; Gottlieb E
Nature; 2011 Aug; 477(7363):225-8. PubMed ID: 21849978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
